Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A low grade well differentiated tumor with neuroendocrine differentiation that arises from the pancreas. The mitotic count is less than 2 per 10 HPF and/or the Ki67 index is equal or less than 2%.
Biomarker and diagnostic research for pancreatic neuroendocrine tumor G1 has been reported in the published literature.
1 clinical trial registered. Interventions under study include drug therapy and procedural interventions. Pipeline includes 1 PHASE4. Research is primarily sponsored by academic and government institutions.
236 publications have been identified in PubMed for pancreatic neuroendocrine tumor G1. Research spans Clinical Trial Publication (21%), Diagnostic / Biomarker (20%), and Case Report / Case Series (19%).
Research Type | Count | % of Total |
|---|---|---|
Clinical study results | 50 |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 2:36 PM UTC
Testing and diagnosis research | 47 | 20% |
Patient case studies | 44 | 19% |
Disease patterns and progression | 37 | 16% |
Research summaries | 29 | 12% |
Laboratory research | 21 | 9% |
New treatment approaches | 8 | 3% |
Lamberti G (2026). [PMID: 41634999](https://pubmed.ncbi.nlm.nih.gov/41634999/). *J Neuroendocrinol*. [Epidemiology / Natural History]
Can C (2026). [PMID: 41545070](https://pubmed.ncbi.nlm.nih.gov/41545070/). *J Nucl Med*. [Gene Therapy / Novel Therapeutics]
Vyas M (2026). [PMID: 41717808](https://pubmed.ncbi.nlm.nih.gov/41717808/). *Am J Surg Pathol*. [Diagnostic / Biomarker]
Belev B (2026). [PMID: 41812599](https://pubmed.ncbi.nlm.nih.gov/41812599/). *Surg Oncol*. [Diagnostic / Biomarker]
Scalorbi F (2026). [PMID: 41702995](https://pubmed.ncbi.nlm.nih.gov/41702995/). *Sci Rep*. [Case Report / Case Series]
Choi GW (2026). [PMID: 41680035](https://pubmed.ncbi.nlm.nih.gov/41680035/). *Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]*. [Basic Science / Preclinical]
Matsuda K (2026). [PMID: 41895782](https://pubmed.ncbi.nlm.nih.gov/41895782/). *Anticancer Res*. [Case Report / Case Series]
Nanashima A (2026). [PMID: 41487921](https://pubmed.ncbi.nlm.nih.gov/41487921/). *Cancer diagnosis & prognosis*. [Basic Science / Preclinical]
Jung S (2026). [PMID: 42067925](https://pubmed.ncbi.nlm.nih.gov/42067925/). *Cardiooncology*. [Epidemiology / Natural History]
Paul A (2026). [PMID: 41712302](https://pubmed.ncbi.nlm.nih.gov/41712302/). *Cancer Control*. [Clinical Trial Publication]
AI-curated news mentioning pancreatic neuroendocrine tumor G1
Updated Jun 8, 2026
Recent research highlights pancreatic neuroendocrine tumors as part of the tumor spectrum associated with Lynch syndrome, indicating a broader impact of mismatch repair deficiency. This discovery could influence future screening and treatment strategies for affected patients.
A recent case report details the occurrence of metachronous primary pancreatic neuroendocrine tumor alongside adenocarcinoma. This study contributes to the understanding of pancreatic tumors and their potential interactions.
A recent study identifies significant intra-pancreatic fat deposition as an independent prognostic factor in high-grade pancreatic neuroendocrine neoplasms. This discovery could influence future research and treatment strategies for this rare cancer type.